Table 3. Predictive models for worsening during the first week among mild patients at admission.
| A) | B (SE) | Wald | p | OR (95% CI) |
| SpO2 <93% | 1.46 (0.45) | 10.15 | <0.001 | 4.32 (1.75–10.62) |
| Sex (male) | -1.33(0.60) | 4.90 | 0.027 | 3.84 (1.17–12.5) |
| No oral corticosteroids | -1.05 (0.46) | 4.73 | 0.030 | 2.77 (1.11–7.14) |
| CRP >67 mg/L | 1.87 (0.48) | 15.07 | <0.001 | 6.54 (2.53–16.88) |
| NLR ≥5.86 | 1.96 (0.56) | 12.28 | <0.001 | 7.15 (2.38–21.49) |
| Monocytes <0.315 x 109/L | 1.69 (0.49) | 11.84 | 0.001 | 5.42 (2.07–14.22) |
| B) | ||||
| SpO2 <93% | 1.87 (0.56) | 10.92 | 0.001 | 6.49 (2.14–19.69) |
| Sex (male) | 1.43 (0.67) | 4.53 | 0.033 | 4.34 (1.12–16.66) |
| CRP >67 mg/L | 1.23 (0.55) | 4.94 | 0.026 | 3.44 (1.15–10.22) |
| NLR ≥5.86 | 1.84 (0.64) | 8.15 | 0.004 | 6.31 (1.78–22.40) |
| Monocytes <0.315 x 109/L | 1.93 (0.60) | 10.18 | 0.001 | 6.94 (2.11–22.85) |
| IL-8 >9.98 pg/mL | 2.18 (0.91) | 5.73 | 0.017 | 8.88 (1.48–53.13) |
| MIP-1β >20.4 pg/mL | 1.34 (0.64) | 4.44 | 0.037 | 3.83 (1.08–13.58) |
| sCD25 >2080 pg/mL | 1.36 (0.65) | 4.36 | 0.037 | 3.91 (1.08–14.08) |
A) Model carried out only with clinical parameters and routine laboratory parameters, Nagelkerke R2, 0.482. Hosmer-Lemeshow χ2, 10.25, p = 0.247. B) Model carried out with clinical parameters, routine laboratory parameters and pro-inflammatory cytokines. Nagelkerke R2, 0.625. Hosmer-Lemeshow χ2 3.62, df 8; p = 0.889. B, beta coefficient; SE, standard error; OR, odds ratio; SpO2, peripheral capillary oxygen saturation; CRP, C-reactive protein; NLR, neutrophil/lymphocyte ratio; IL-8, interleukine-8; MIP-1β, macrophage inflammatory proteins 1β; sCD25, interleukine-2 soluble receptor.